CN101002858A - Medicine composition for enhancing immunity, and its preparing method and use - Google Patents
Medicine composition for enhancing immunity, and its preparing method and use Download PDFInfo
- Publication number
- CN101002858A CN101002858A CNA2006101713336A CN200610171333A CN101002858A CN 101002858 A CN101002858 A CN 101002858A CN A2006101713336 A CNA2006101713336 A CN A2006101713336A CN 200610171333 A CN200610171333 A CN 200610171333A CN 101002858 A CN101002858 A CN 101002858A
- Authority
- CN
- China
- Prior art keywords
- pachyman
- poria
- cmp
- radix ginseng
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000036039 immunity Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims description 18
- 230000002708 enhancing effect Effects 0.000 title description 9
- 229940079593 drug Drugs 0.000 title description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 41
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 41
- 235000008434 ginseng Nutrition 0.000 claims abstract description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 42
- 241000208340 Araliaceae Species 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 32
- 239000012670 alkaline solution Substances 0.000 claims description 28
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000003916 acid precipitation Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 229940040145 liniment Drugs 0.000 claims description 4
- 239000000865 liniment Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000241838 Lycium barbarum Species 0.000 abstract description 8
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 8
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 8
- 235000013399 edible fruits Nutrition 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 235000008599 Poria cocos Nutrition 0.000 abstract description 2
- 230000036528 appetite Effects 0.000 abstract description 2
- 235000019789 appetite Nutrition 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 77
- 239000000243 solution Substances 0.000 description 65
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 239000000706 filtrate Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 26
- 238000012360 testing method Methods 0.000 description 24
- 229960004756 ethanol Drugs 0.000 description 21
- 239000012153 distilled water Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 239000000376 reactant Substances 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000242 pagocytic effect Effects 0.000 description 13
- 238000000108 ultra-filtration Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 230000001476 alcoholic effect Effects 0.000 description 12
- 102000003390 tumor necrosis factor Human genes 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 206010018910 Haemolysis Diseases 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 230000008588 hemolysis Effects 0.000 description 10
- 239000011265 semifinished product Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- -1 acetyl pachymic acid Chemical compound 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 229930182494 ginsenoside Natural products 0.000 description 8
- 229940089161 ginsenoside Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 7
- 229940106681 chloroacetic acid Drugs 0.000 description 7
- 239000012510 hollow fiber Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 208000033065 inborn errors of immunity Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910017604 nitric acid Inorganic materials 0.000 description 6
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001597008 Nomeidae Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 102000011759 adducin Human genes 0.000 description 5
- 108010076723 adducin Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000001117 sulphuric acid Substances 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 241000201295 Euphrasia Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- BWSIKGOGLDNQBZ-LURJTMIESA-N (2s)-2-(methoxymethyl)pyrrolidin-1-amine Chemical compound COC[C@@H]1CCCN1N BWSIKGOGLDNQBZ-LURJTMIESA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical group [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 2
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008876 liujunzi Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101713336A CN100534474C (en) | 2006-12-19 | 2006-12-19 | Medicine composition for enhancing immunity, and its preparation method and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101713336A CN100534474C (en) | 2006-12-19 | 2006-12-19 | Medicine composition for enhancing immunity, and its preparation method and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101002858A true CN101002858A (en) | 2007-07-25 |
CN100534474C CN100534474C (en) | 2009-09-02 |
Family
ID=38702384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101713336A Active CN100534474C (en) | 2006-12-19 | 2006-12-19 | Medicine composition for enhancing immunity, and its preparation method and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100534474C (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697047A (en) * | 2012-06-11 | 2012-10-03 | 宁夏红中宁枸杞制品有限公司 | Method for preparing oral liquid of Chinese wolfberry |
CN101455371B (en) * | 2008-11-27 | 2012-10-03 | 成都润馨堂药业有限公司 | Health-care product containing buckwheat flavone and preparation method thereof |
CN103584096A (en) * | 2013-11-15 | 2014-02-19 | 大连杰信生物科技有限公司 | Preparation and effect of immunity-strengthening health-care cream |
CN103798772A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Health-care product composition |
CN103798774A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Compound poria cocos preparation |
CN104432062A (en) * | 2014-12-18 | 2015-03-25 | 广州纽健生物科技有限公司 | Antitumor food containing carboxymethyl pachyman |
CN104489516A (en) * | 2014-12-03 | 2015-04-08 | 姜秀清 | Health-preserving porridge capable of improving postoperative immune function of cancer paint and preparation method for health-preserving porridge |
CN104585769A (en) * | 2015-02-13 | 2015-05-06 | 福建天斯顿生物科技有限公司 | Allicin-containing compound product and preparation method for compound product |
CN105294872A (en) * | 2015-10-14 | 2016-02-03 | 四川农业大学 | Preparation method of carboxymethylated catathelasma ventricosum polysaccharide |
CN105963343A (en) * | 2016-05-14 | 2016-09-28 | 运城学院 | Compound radix codonopsis total saponins and immunopolysaccharides nano emulsion composition and preparation method thereof |
CN106491830A (en) * | 2016-11-15 | 2017-03-15 | 东莞自然衡健康科技有限公司 | Soft capsule of enhancing immunity and preparation method thereof |
CN106511485A (en) * | 2016-10-27 | 2017-03-22 | 无限极(中国)有限公司 | Chinese herbal medicinal polysaccharide composition and application thereof |
CN108720019A (en) * | 2018-08-22 | 2018-11-02 | 湖南中医药大学 | A kind of nutrition brewed powder and preparation method thereof that Cancer related fatigue is mitigated or eliminated |
CN108853337A (en) * | 2018-08-22 | 2018-11-23 | 湖南中医药大学 | A kind of herbal cuisine and preparation method thereof for Cancer related fatigue to be mitigated or eliminated |
CN108968066A (en) * | 2018-07-11 | 2018-12-11 | 北京理工亘舒科技有限公司 | A kind of ginseng of strengthen immunity, Rhizoma Atractylodis Macrocephalae, Poria cocos, herbal cuisine element product of fructus lycii and preparation method thereof |
CN108991529A (en) * | 2018-08-22 | 2018-12-14 | 湖南中医药大学 | The food compositions and preparation method thereof of member are supported in a kind of invigorating the spleen |
CN109248177A (en) * | 2018-08-23 | 2019-01-22 | 许瑞安 | The preparation of crocodile first active principle and its anti-oxidant, anti-hepatic fibrosis application |
CN109805233A (en) * | 2019-03-07 | 2019-05-28 | 湖南补天药业股份有限公司 | A kind of Poria cocos beverage and preparation method thereof with promotion efficacy of immunity |
CN109970880A (en) * | 2019-04-02 | 2019-07-05 | 广州华农大实验兽药有限公司 | A kind of preparation method of ginseng leaf polyose |
CN110236183A (en) * | 2019-05-24 | 2019-09-17 | 成都大学 | A method of it being used to prepare the composition of quinoa ferment and its prepares ferment |
CN110613793A (en) * | 2019-10-14 | 2019-12-27 | 福建省中医药研究院(福建省青草药开发服务中心) | Anti-tumor composition and preparation method and application thereof |
CN110893222A (en) * | 2019-12-02 | 2020-03-20 | 江苏康缘药业股份有限公司 | Composition with function of improving immunity and preparation method thereof |
CN111840346A (en) * | 2020-08-26 | 2020-10-30 | 安发(福建)生物科技有限公司 | Traditional Chinese medicine composition for enhancing immunity and preparation method and application thereof |
CN112450443A (en) * | 2020-11-09 | 2021-03-09 | 陕西中延再生医学研究院有限公司 | Functional food for repairing DNA damage and recovering cell regeneration |
CN115245554A (en) * | 2021-04-27 | 2022-10-28 | 湖南补天药业股份有限公司 | Poria cocos medicinal composition with stomach invigorating and spleen eliminating effects and application thereof |
-
2006
- 2006-12-19 CN CNB2006101713336A patent/CN100534474C/en active Active
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101455371B (en) * | 2008-11-27 | 2012-10-03 | 成都润馨堂药业有限公司 | Health-care product containing buckwheat flavone and preparation method thereof |
CN102697047A (en) * | 2012-06-11 | 2012-10-03 | 宁夏红中宁枸杞制品有限公司 | Method for preparing oral liquid of Chinese wolfberry |
CN103798772A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Health-care product composition |
CN103798774A (en) * | 2012-11-12 | 2014-05-21 | 苏州市洋海电子有限公司 | Compound poria cocos preparation |
CN103584096A (en) * | 2013-11-15 | 2014-02-19 | 大连杰信生物科技有限公司 | Preparation and effect of immunity-strengthening health-care cream |
CN104489516A (en) * | 2014-12-03 | 2015-04-08 | 姜秀清 | Health-preserving porridge capable of improving postoperative immune function of cancer paint and preparation method for health-preserving porridge |
CN104432062A (en) * | 2014-12-18 | 2015-03-25 | 广州纽健生物科技有限公司 | Antitumor food containing carboxymethyl pachyman |
CN104585769A (en) * | 2015-02-13 | 2015-05-06 | 福建天斯顿生物科技有限公司 | Allicin-containing compound product and preparation method for compound product |
CN104585769B (en) * | 2015-02-13 | 2016-08-17 | 福建天斯顿生物科技有限公司 | A kind of compound product containing allicin and preparation method thereof |
CN105294872A (en) * | 2015-10-14 | 2016-02-03 | 四川农业大学 | Preparation method of carboxymethylated catathelasma ventricosum polysaccharide |
CN105294872B (en) * | 2015-10-14 | 2017-10-13 | 四川农业大学 | A kind of preparation method of the luxuriant mushroom polysaccharide of carboxy methylation shuttle handle pine |
CN105963343A (en) * | 2016-05-14 | 2016-09-28 | 运城学院 | Compound radix codonopsis total saponins and immunopolysaccharides nano emulsion composition and preparation method thereof |
CN106511485A (en) * | 2016-10-27 | 2017-03-22 | 无限极(中国)有限公司 | Chinese herbal medicinal polysaccharide composition and application thereof |
CN106491830A (en) * | 2016-11-15 | 2017-03-15 | 东莞自然衡健康科技有限公司 | Soft capsule of enhancing immunity and preparation method thereof |
CN108968066A (en) * | 2018-07-11 | 2018-12-11 | 北京理工亘舒科技有限公司 | A kind of ginseng of strengthen immunity, Rhizoma Atractylodis Macrocephalae, Poria cocos, herbal cuisine element product of fructus lycii and preparation method thereof |
CN108720019A (en) * | 2018-08-22 | 2018-11-02 | 湖南中医药大学 | A kind of nutrition brewed powder and preparation method thereof that Cancer related fatigue is mitigated or eliminated |
CN108991529B (en) * | 2018-08-22 | 2021-09-03 | 湖南中医药大学 | Food composition for invigorating spleen and nourishing vitality and preparation method thereof |
CN108991529A (en) * | 2018-08-22 | 2018-12-14 | 湖南中医药大学 | The food compositions and preparation method thereof of member are supported in a kind of invigorating the spleen |
CN108853337A (en) * | 2018-08-22 | 2018-11-23 | 湖南中医药大学 | A kind of herbal cuisine and preparation method thereof for Cancer related fatigue to be mitigated or eliminated |
CN109248177A (en) * | 2018-08-23 | 2019-01-22 | 许瑞安 | The preparation of crocodile first active principle and its anti-oxidant, anti-hepatic fibrosis application |
CN109248177B (en) * | 2018-08-23 | 2023-02-28 | 许瑞安 | Preparation of crocodile amour effective component and application of crocodile amour effective component in oxidation resistance and hepatic fibrosis resistance |
CN109805233A (en) * | 2019-03-07 | 2019-05-28 | 湖南补天药业股份有限公司 | A kind of Poria cocos beverage and preparation method thereof with promotion efficacy of immunity |
CN109805233B (en) * | 2019-03-07 | 2022-03-11 | 湖南补天药业股份有限公司 | Poria cocos beverage with immunity improving effect and preparation method thereof |
CN109970880A (en) * | 2019-04-02 | 2019-07-05 | 广州华农大实验兽药有限公司 | A kind of preparation method of ginseng leaf polyose |
CN110236183A (en) * | 2019-05-24 | 2019-09-17 | 成都大学 | A method of it being used to prepare the composition of quinoa ferment and its prepares ferment |
CN110613793A (en) * | 2019-10-14 | 2019-12-27 | 福建省中医药研究院(福建省青草药开发服务中心) | Anti-tumor composition and preparation method and application thereof |
CN110893222A (en) * | 2019-12-02 | 2020-03-20 | 江苏康缘药业股份有限公司 | Composition with function of improving immunity and preparation method thereof |
CN111840346A (en) * | 2020-08-26 | 2020-10-30 | 安发(福建)生物科技有限公司 | Traditional Chinese medicine composition for enhancing immunity and preparation method and application thereof |
CN112450443A (en) * | 2020-11-09 | 2021-03-09 | 陕西中延再生医学研究院有限公司 | Functional food for repairing DNA damage and recovering cell regeneration |
CN115245554A (en) * | 2021-04-27 | 2022-10-28 | 湖南补天药业股份有限公司 | Poria cocos medicinal composition with stomach invigorating and spleen eliminating effects and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100534474C (en) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100534474C (en) | Medicine composition for enhancing immunity, and its preparation method and use | |
CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
CN101450166A (en) | Traditional Chinese medicine composition with blood-sugar function and preparation method thereof | |
CN103070880A (en) | Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes | |
CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
CN103181560B (en) | Health food having effects of life cultivation and health preservation in winter and preparation method thereof | |
CN103463257A (en) | Fructus aurantii immaturus or fructus aurantii extract, its preparation method and application | |
CN105535738A (en) | Traditional Chinese medicine preparation for treating chronic cough and preparing method thereof | |
CN100493578C (en) | Chinese medicine composition for treating thin body and delicate constitution, and preparing method | |
CN105055855A (en) | Traditional Chinese medicine composition having sleep improvement and immunity boost effects as well as preparation method and application of traditional Chinese medicine composition | |
CN100563630C (en) | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation | |
CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
CN103169072A (en) | Ginseng composition, and preparation method and use thereof | |
CN103238834B (en) | A kind of composition treating pruitus and preparation method thereof | |
CN112245527A (en) | Preparation method of active polysaccharide extract, functional beverage and effervescent granule with homology of medicine and food | |
CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
CN105055851A (en) | Chinese medicinal composition for treatment of diabetes, preparation and application thereof | |
CN106722918A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
CN104645121A (en) | Medicine for treating oral ulcer in children | |
CN109528857A (en) | A kind of campanulaceae particle and preparation method thereof for treating respiratory disease caused by haze | |
CN107811907A (en) | A kind of body lotion for promoting subcutaneous fat to decompose | |
CN107325071A (en) | A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect | |
CN112057476B (en) | Composition and application thereof in sobering-up, hangover-relieving and stomach-protecting | |
CN101874840A (en) | Total polysaccharide extractive of morinda plants as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN BUTIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: DAI JIAMU Effective date: 20090619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090619 Address after: Hunan province Changsha Furong Road No. 218 building room 2109-2111 and post encoding: 410005 Applicant after: Hunan Bu Tian Pharmaceutical Co., Ltd. Co-applicant after: Dai Jiamu Address before: Hunan province Changsha Furong Road No. 218 building room 2109-2111 and post encoding: 410005 Applicant before: Dai Jiamu |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hunan Butian Pahrmaceutical Co., Ltd. Assignor: Dai Jiamu|Hunan BuTian Pharmaceutical Co. Ltd. Contract record no.: 2012430000022 Denomination of invention: Medicine composition for enhancing immunity, and its preparing method and use Granted publication date: 20090902 License type: Exclusive License Open date: 20070725 Record date: 20120401 |
|
CP01 | Change in the name or title of a patent holder |
Address after: 410005 room 2109-2111, Ho Fu mansion 218, Furong Middle Road, Changsha, Hunan. Co-patentee after: Dai Jiamu Patentee after: Hunan Butian pharmaceutical Limited by Share Ltd Address before: 410005 room 2109-2111, Ho Fu mansion 218, Furong Middle Road, Changsha, Hunan. Co-patentee before: Dai Jiamu Patentee before: Hunan Butian Pahrmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
DD01 | Delivery of document by public notice |
Addressee: Hunan Butian Pahrmaceutical Co., Ltd. Document name: Notification that Application Deemed not to be Proposed |
|
DD01 | Delivery of document by public notice | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 418000 erlianting, Huancheng South Road, Quyang Town, Jingzhou County, Huaihua City, Hunan Province Co-patentee after: Dai Jiamu Patentee after: HUNAN BUSKY PHARMACEUTICAL Co.,Ltd. Address before: 410005 Hunan province Changsha Furong Road No. 218 and building room 2109-2111 Co-patentee before: Dai Jiamu Patentee before: HUNAN BUSKY PHARMACEUTICAL Co.,Ltd. |